Clinical marker associated with cerebral aneurysms and application of clinical marker

A cerebral aneurysm, clinical application technology, applied in the field of clinical markers, can solve the problems of lagging and inability to diagnose early aneurysms, etc., and achieve high reliability, high precision and effective risk of cerebral aneurysm, high precision and effective determination Effect

Active Publication Date: 2018-01-09
李永东
View PDF8 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the diagnosis, prognosis and evaluation of intracranial aneurysms mainly rely on imaging, hemodynamics, and biological model establishment. These methods have obvious lags and cannot be used for early diagnosis of aneurysms.
An effective method for accurate, rapid and large-scale detection of unruptured intracranial aneurysms is currently lacking

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] This example is the extraction and identification of serum exosomes.

[0049] Extract 5ml of arterial blood or peripheral venous blood from cerebral aneurysm patients (n=10) or normal controls (n=10), and use high-speed centrifugation or kits to extract exosome microRNA. The extracted exosomes were then identified by electron microscopy, Western Blotting and / or flow cytometry.

Embodiment 2

[0051] The purpose of this example is to discover the differential exosomal microRNAs of cerebral aneurysms.

[0052] Using the Illumina HiSeqTM2500 sequencing method or gene probe method, bioinformatics analysis was performed on the measured data, and the difference of exosomal microRNA in the case (brain aneurysm) group and the control (no brain aneurysm) group was investigated and carried out. Case-related analysis revealed 24 statistically significant differential exosomal microRNAs associated with aneurysm development.

Embodiment 3

[0054] In this example, 24 differential exosomal microRNAs were verified by qPCR.

[0055] 24 exosomal microRNAs were validated by qPCR in 154 aneurysm samples and 55 normal control samples. Then calculate the relative expression level of microRNA by the formula 2 -ΔΔCt , and compared with the relative expression level of the external reference cel-miR-392 -ΔΔCt Compared, it was found that exosomal miR-628-3p, miR-505-5p, miR-3074-3p, miR-497-5p, miR-224-5p, miR-181b-3p and let-7b-5p, Especially exosomal miR-628-3p is very useful as a clinical marker of cerebral aneurysm. When we set the relative expression level of exosomes in serum samples2 -ΔΔCt When the value is ≥5 or more than 10 times compared with the normal control, the accuracy and sensitivity of exosomal miR-628-3p in diagnosing cerebral aneurysms are above 85%, which can be used as a clinical marker of cerebral aneurysm in the diagnosis Clinically most cerebral aneurysms. Furthermore, by combining these exosoma...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a clinical marker associated with cerebral aneurysms. The clinical marker comprises one or more of miR-628-3p, miR-505-5p, miR-3074-3p, miR-497-5p, miR-224-5p, miR-181b-5p andlet-7b-5p. The invention also relates to a kit for detecting onset of the cerebral aneurysms or a kit for diagnosing the cerebral aneurysms. The kit contains any one or more of the clinical markers and corresponding primers of the clinical markers. The invention also relates to an application of the kit in a determining method for diagnosing the onset of the cerebral aneurysms or a clinical application in diagnosis of the cerebral aneurysms. The fact that exosome miR-628-3p as a clinical marker of the cerebral aneurysms has quite high accuracy is discovered for the first time. The onset of thecerebral aneurysms can be judged more accurately if the miRNA markers are combined, that is, diagnosis results with higher reliability can be obtained by using the exosome miRNA clinical marker of the cerebral aneurysms and the determining method for diagnosing the onset of the cerebral aneurysms.

Description

technical field [0001] The invention relates to the fields of genetic engineering and neurology, in particular to a clinical marker related to cerebral aneurysm and its application. Background technique [0002] Cerebral aneurysm is a cerebral hemangioma-like protrusion produced by localized weak and bulging walls. Subarachnoid hemorrhage (SAH) is one of the most common cerebrovascular diseases after its rupture. Next to cerebral infarction and hypertensive cerebral hemorrhage, the annual incidence is about 8-16 cases per 100,000 people, and about 80% of subarachnoid hemorrhage is caused by aneurysm. After aneurysm rupture, the mortality rate reaches 40%, the disability rate reaches 33%, and if it is not diagnosed and treated in time, the mortality rate reaches 60% within 2 years. It is generally believed that the incidence of unruptured aneurysms in the adult population is 2%-7%, and the incidence increases with age. Intracranial aneurysm is like a "time bomb" left in the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886C12N15/113
Inventor 李永东
Owner 李永东
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap